TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Brett Johnson, President and Executive Editor of OneMedPlace, interviewed Biovest’s President and CEO, Samuel S. Duffey, and its Senior Vice President, Product Development & Regulatory Affairs, Carlos F. Santos, Ph.D. In the webcast audio interview on OneMedRadio, Biovest discussed its global regulatory strategy for BiovaxID®, Biovest’s personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma.
